Hartmut Derendorf
Overview
Explore the profile of Hartmut Derendorf including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
225
Citations
4085
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Derendorf H, Heinrichs T, Reimers T, Lebert C, Brinkmann A
GMS Infect Dis
. 2020 May;
8:Doc17.
PMID: 32373442
This is the third chapter of the guideline "Calculated initial parenteral treatment of bacterial infections in adults - update 2018" in the 2 updated version. The German guideline by the...
12.
Galvao J, Santos R, Silva A, Santos J, Costa A, Chandasana H, et al.
Eur J Pharm Sci
. 2020 Apr;
150:105335.
PMID: 32272211
Leishmaniasis are a group of neglected infectious diseases caused by protozoa of the genus Leishmania with distinct presentations. The available leishmaniasis treatment options are either expensive and/or; cause adverse effects...
13.
14.
Ravula A, Chandasana H, Jagnarine D, Wall S, Setlow B, Febo M, et al.
Cannabis Cannabinoid Res
. 2020 Feb;
4(4):240-254.
PMID: 32042924
Cannabis is the most widely used illicit drug in the US, and cannabis use among young adults continues to rise. Previous studies have shown that chronic administration of delta 9-tetrahydrocannabinol...
15.
Eyal S, Derendorf H
Pharm Res
. 2019 Aug;
36(10):148.
PMID: 31414302
Medications have been used during space missions for more than half a century, yet our understanding of the effects of spaceflight on drug pharmacokinetics and pharmacodynamics is poor. The space...
16.
F Voelkner N, Voelkner A, Derendorf H
Curr Protoc Pharmacol
. 2019 Apr;
85(1):e58.
PMID: 31026128
The evaluation of absorption and availability at the site of action of a drug candidate is an important element of drug discovery and development, as clinical response is a function...
17.
Derendorf H, von Richter O, Hermann R, Rostami-Hodjegan A
Clin Pharmacol Ther
. 2019 Apr;
105(6):1289-1291.
PMID: 30977519
No abstract available.
18.
Li G, Zheng Q, Yu Y, Zhong W, Zhou H, Qiu F, et al.
Clin Pharmacokinet
. 2019 Feb;
58(7):927-941.
PMID: 30767128
Background: The vast majority of physiological and biological data required for physiologically based predictions are primarily available in Caucasians rather than other ethnic populations, which leads to a lack of...
19.
Yu G, Zheng Y, Yu Y, Li G, Derendorf H
Drug Discov Today
. 2019 Jan;
24(3):845-857.
PMID: 30648608
Drug-drug interactions (DDIs) between direct-acting antiviral (DAA) medications and acid-reducing agents mediated by gastric acid represent an important issue in drug development and treatment, which could lead to impaired bioavailability...
20.
Prasanchaimontri I, Chandasana H, Akbar M, Swarts S, Okuneiff P, Derendorf H
Eur J Pharm Biopharm
. 2018 Dec;
135:83-93.
PMID: 30582960
Fibroblast growth factor peptide (FGF-P) is a polypeptide analog of FGF-2 that could be a potential mitigation and treatment agent for radiation syndromes. Prior to conducting preclinical pharmacokinetics, we developed...